Granules India has received USFDA approval for their generic ADHD medication, Amphetamine extended-release tablets. The drug, ...

Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic medication ...

Granules India has secured tentative approval from the USFDA for its generic ADHD medication. This approval is for ...

The product has an estimated market size of around $172 million as per IQVIA (IMS Health), Granules said. At present, the ...

The latest announcement is out from Granules India Limited ( ($IN:GRANULES) ). Granules Pharmaceuticals Inc., the US-based wholly owned subsidiary ...

Hyderabad: Granules Pharmaceuticals, a wholly owned subsidiary of Granules India, has received tentative approval from the ...

Granules India secures U.S. FDA tentative approval for its ADHD generic, enhancing access to critical therapy and expanding its generics portfolio.

The inspection was conducted from December 15 to December 19, 2025, and concluded with five observations related to procedural requirements. The company said none of the observations are associated ...

Granules India receives USFDA approval for generic Amphetamine tablets for ADHD. Expands US portfolio & CNS presence. Market ...

Granules India received USFDA approval for their generic ADHD medication, Amphetamine extended-release tablets, which will be ...